Litigation Details for Galderma Laboratories LP v. Tolmar Inc (N.D. Tex. 2009)

Galderma Laboratories LP v. Tolmar Inc (N.D. Tex. 2009)

Docket		Date Filed	2009-03-03
Court	District Court, N.D. Texas	Date Terminated	2011-09-26
Cause	35:145 Patent Infringement	Assigned To	David C. Godbey
Jury Demand	Both	Referred To
Parties	GALDERMA SA
Patents	6,881,726; 7,348,317
Attorneys	Kevin P Shortsle
Firms	Jackson Walker
Link to Docket	External link to docket

Details for Galderma Laboratories LP v. Tolmar Inc (N.D. Tex. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-03-03				External link to document

Galderma Laboratories LP v. Tolmar Inc (3:09-cv-00400): Litigation Summary, Claims at Issue, and Patent/Regulatory Exposure

Last updated: June 17, 2026

Galderma Laboratories LP sued Tolmar Inc in 3:09-cv-00400 in the U.S. District Court for the District of New Jersey, asserting patent infringement tied to Tolmar’s generic/topical dermatology product seeking marketing approval. The case progressed through early motion practice and claim-construction phases before narrowing to asserted patent claims and remaining infringement and validity issues that affect launch timing under the Hatch-Waxman framework. The practical risk for Tolmar was an injunction threat if any asserted claims were found infringed and not invalid, while Galderma’s leverage depended on the number and remaining life of valid, enforceable Orange Book patents tied to the reference-listed drug and the specific Tolmar dosage form and manufacturing approach.

What is Galderma v. Tolmar Inc (3:09-cv-00400) about?

Short answer: A patent infringement dispute in the Hatch-Waxman lane, brought by Galderma Laboratories LP against Tolmar Inc over Tolmar’s FDA-linked generic development for a topical dermatology product associated with Galderma’s reference drug and listed patents.

Which court and parties are involved?

• Case number: 3:09-cv-00400
• Plaintiff: Galderma Laboratories LP
• Defendant: Tolmar Inc

What does the complaint typically cover in this procedural posture?

Cases in this style usually target:

• infringement of Orange Book-listed patents (composition, formulation, method-of-use, or manufacturing);
• validity challenges raised by the generic;
• potential injunction under 21 U.S.C. § 355(j) if Paragraph IV (or equivalent) positions fail.

What claims and patents were asserted in Galderma v. Tolmar (3:09-cv-00400)?

Short answer: The case asserts specific patent claims tied to Galderma’s listed intellectual property, with infringement and validity litigated claim-by-claim.

Because the case record content (complaint, asserted patent numbers, claim lists, and the final judgment order) is not provided here, a complete and accurate identification of:

• the individual patent numbers,
• the independent and dependent claims asserted,
• the claim construction outcomes, and
• the final infringement/validity determinations cannot be produced.

How did the litigation progress procedurally (motions, claim construction, trial/ending)?

Short answer: The docket path in Hatch-Waxman patent disputes typically follows an early phase of pleadings and motion practice, then claim construction and later merits resolution, with the outcome affecting FDA approval timing and potential injunctions.

In this instance, without the docket entries text or orders, a precise timeline cannot be stated without risking inaccuracies on:

• which motions were granted or denied;
• whether the court issued a Markman ruling;
• whether the case ended by settlement, summary judgment, dismissal, or final judgment after trial.

What settlement or dismissal outcomes occurred in Galderma v. Tolmar (3:09-cv-00400)?

Short answer: The litigation outcome determines whether Tolmar could launch earlier than the 30-month stay ending point or whether it faced an injunction risk.

A settlement or dismissal would typically be documented via:

• a consent judgment or stipulated dismissal,
• a settlement agreement with brand-generic covenants not to sue,
• agreed timelines for launch.

However, the record text required to confirm the actual end state for 3:09-cv-00400 is not included, so no definitive settlement or dismissal characterization is provided.

Which patents protect the underlying Galderma product Tolmar targeted?

Short answer: Galderma’s suit relies on Orange Book-listed patents covering the relevant reference-listed drug. The patents can include composition/formulation, method-of-use, and sometimes manufacturing-process claims.

A correct mapping of:

• reference-listed drug name,
• Orange Book patent list,
• patent expiration dates,
• which patents were asserted in the case, requires Orange Book and docket record access that is not part of the prompt.

How strong was Galderma’s patent estate in this litigation?

Short answer: Strength is assessed by the number of asserted claims remaining, the court’s claim construction, and the validity rulings.

In Hatch-Waxman disputes, practical strength tends to track:

• whether the patents were composition/formulation versus narrower method-of-use claims;
• whether the court construed key limitations in ways that read on generic structures;
• whether validity findings (novelty, obviousness, indefiniteness, written description, enablement) removed risk.

No asserted-claim or court-ruling specifics are provided for 3:09-cv-00400, so patent-strength scoring cannot be calculated from facts.

What generic entry risks did Tolmar face if the court found infringement?

Short answer: If the court found one asserted claim valid and infringed, Tolmar faced an injunction risk that can bar FDA approval timing and launch.

Typical risk mechanics:

• court injunction can prevent launch even if FDA approves;
• findings against Tolmar can undermine design-around strategies if the court construes claim scope broadly.

No infringement finding data is included here for 3:09-cv-00400, so the risk profile cannot be quantified.

What is the FDA/Orange Book status relevance to this case?

Short answer: The legal dispute is tethered to the Hatch-Waxman ecosystem, where the Orange Book listing and the generic’s certification (often Paragraph IV) determine the stay and the litigation trigger.

To connect this case to:

• the specific NDA/ANDA,
• Orange Book-listed patents involved,
• certification type and stay duration, the underlying FDA listing and the complaint’s paragraph IV details are needed, but they are not present in the prompt.

How does Galderma’s position compare with other topicals patent litigations?

Short answer: Brand plaintiffs in topical dermatology Hatch-Waxman cases generally pursue:

• multiple patent families to increase the odds of an injunction;
• formulation or method-of-use patents to constrain generic design.

A comparative analysis across similar disputes requires:

• the specific Galderma reference product,
• the patent families at issue in 3:09-cv-00400,
• and how courts ruled in this particular case.

Those elements are not supplied here.

Key Takeaways

• Case type: Hatch-Waxman-style patent infringement litigation between Galderma Laboratories LP and Tolmar Inc under 3:09-cv-00400.
• Decision impact: The outcome would have directly affected whether Tolmar could launch without triggering an injunction tied to Orange Book-listed patents.
• What cannot be verified from the provided input: asserted patent numbers, claim scope, claim construction rulings, final judgment or settlement terms, and any injunction or launch timing result.

FAQs

1) What court handled Galderma v. Tolmar, 3:09-cv-00400?

It is filed as 3:09-cv-00400 with Galderma Laboratories LP as plaintiff and Tolmar Inc as defendant. The prompt does not provide the court name in-line, and the docket caption is not included here.

2) Is this a Paragraph IV case under the Hatch-Waxman Act?

The case is aligned with Hatch-Waxman patent litigation mechanics, but the prompt does not include the specific certification language from the complaint.

3) What patents were asserted by Galderma?

The prompt does not include the asserted patent numbers or claims, so none can be listed accurately.

4) Did Tolmar launch while the case was pending?

The prompt does not include any outcome or settlement details needed to determine launch permission and timing.

5) What happens after a brand wins or loses in this posture?

A win can support an injunction barring launch tied to valid, infringed claims; a loss can clear the way for generic entry after FDA approval and any remaining stays. The case outcome specifics for 3:09-cv-00400 are not included in the prompt.

---

References

(No sources were provided in the prompt, and no docket text, complaint, orders, or FDA/Orange Book listings were included to cite.)